(+20) 11 4444 5474

Switch Therapeutics came out of stealth mode this week announcing $52M in early funding to develop conditionally activated small interfering (CASi) RNA therapeutics.

Switch scientists have created a first-of-its-kind RNA interference (i) technology combined with nucleic acid nanotechnology that allows therapy to be highly cell selective and also has efficient delivery, uptake, potency, and duration of treatment effect.

The founders are hoping to overcome known limitations of antisense oligonucleotide (ASO) and siRNA therapies, which includes limited targeting abilities, distribution requiring lipid nanoparticles (LNPs) or targeting ligands, and limited potency.

“This is a transformational era for RNA medicines and we’re excited to apply our scientific discoveries in ways that could lead to new therapeutic breakthroughs, with the potential to treat some of the most devastating diseases,” said Dee Datta, co-founder, and CEO of Switch, in a press statement.

“Our approach uses novel CASi molecules that are uniquely able to self-deliver efficiently, have high potency, and long duration of effect. Additionally, we can design CASi molecules to activate only in select cells, allowing for expansion into targets that may require precision RNAi approaches.”

The company’s approach involves taking advantage of the properties of both single and double-stranded RNA and includes a specific “sensor” in the therapy being developed to allow better targeting of specific cells in the body.

Switch was founded by Datta and Si-ping Han, now CTO, in 2020 and is based on many years of research on RNAi by Caltech professor Bill Goddard; City of Hope molecular and cellular biology leader John Rossi; discovery biology director Lisa Scherer, Harvard medical professor Saumya Das and Han.

Both Datta and Han previously worked with Goddard, who has helped set up a number of biotechs in the past. For example, Datta and Goddard founded Allozyne together, a biotech focusing on multiple sclerosis, which was broken up in 2014 after a failed merger with most of its patents and technologies subsequently sold to AstraZeneca and MedImmune.

Initially starting at incubator MBC Biolabs, Switch moved into its own premises in 2022 in South San Francisco. The first funding round has raised $52 million from UCB Ventures, Insight Partners, Eli Lilly, BOLD Capital Partners, Ono Venture Investment, Wilson Hill, as well as other VC firms.

“With its pioneering science that could have broad therapeutic applications, Switch is at the forefront of evolving what’s possible with RNA-based approaches to medicine,” said Alicia Irurzun-Lafitte, Partner of UCB Ventures, a co-lead investor. “UCB Ventures is passionate about funding innovative companies and we are pleased to support Switch as it works to realize the potential of the CASi platform and its future impact for patients.”

Together Against Cancer

hot clinic

 

 

 

 

 

 

 

 

Newsletter

Contact Us

mapBorg Elfarag building,
Algalaa street (previously Baby Coca street), Off Alex-Cairo Agricultural Road, Semouha Algadeeda, Alexandria , EGYPT

map(+20) 11 4444 5474